Event Schedule, September 15, 2025
8:00 - 9:00 am
9:00 am
9:30 am
9:30 am - 3:00 pm
Lunch pickup at the turn
10:30 at driving range
3:00 - 3:30 pm
3:30 - 4:30 pm
-
Arrival and Check-In outside of Clubhouse
-
Light breakfast and coffee will be provided
-
Purchase tickets, mulligans, and entry to play games on course (cash and credit card accepted)
-
Free bucket of balls for driving range
-
Gather for remarks, directions, and rules of the day
-
Shot Gun Start
-
18 hole golf
-
Charity games at various holes
-
11 am lunch starts, pick up hot dogs and hamburgers between holes 9 and 10
-
Drink cart
-
Helicopter Ball Drop (driving range closed until 10:45)
-
Putting competition finals
-
Dinner, programming, awards ceremony, raffle winners drawn
Prize Information:
Southwest Airlines tickets: Winners will receive Southwest flights in the form of One-Way tickets valued at $200 each.Furthest from the Pin: Winner will receive a $350 check from Partners for Cancer Care and Prevention, Inc. Winner is not allowed to decline winnings as a "donation" to the organization.
We are the patient- and caregiver-focused central hub for education and connections to resources about peritoneal surface malignancies, including advanced gastrointestinal and gynecologic cancers, and the lifesaving Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) treatment option.
Awareness

Connection

Navigation

We have assembled a network of people and organizations that make better treatment a reality, improving the outcomes for patients and families of those with a variety of intra-abdominal malignancies in advanced stages.

Together we are part of the solution.
Dr. Armando Sardi, President and Co-Founder

OUR MISSION
Is to advocate for cancer patients by making connections, providing education, and guiding patient navigation to improve the quality and length of their life; with a focus on breast, cervical, and abdominal cancers.

OUR PROGRAMS
In North America and South America continue to significantly increase patients’ chances of long-term survival and potential cure.
The Abdominal Cancers Alliance (the Alliance), a patient-led organization, is a central education and information hub providing resources and accurate, updated information to patients and families about abdominal cancers and CRS/HIPEC treatment options (Cytoreductive Surgery /Hyperthermic (or Heated) Intraperitoneal Chemotherapy).
The Abdominal Cancers Alliance assists patients in getting the proper information regarding their cancer treatment in a timely manner and connects them with organizations, other patients, and the medical community, to provide resources in all phases of the patient journey from diagnosis to treatment and survivorship.

Join our Patient and Caregiver Network
Wherever you may be located, fill out our interest form to:
-
stay up to date with all of our resource launches,
-
get connected with events at our developing hubs,
-
and join our patient network!
Our patient and caregiver network works to connect patients and caregivers to others who have gone through similar experiences based on cancer or treatment type or live in the same area based on preferences collected in the interest form.

PFCCAP’s inception program focuses on mitigating the obstacles women face in their breast and cervical cancer journeys by bridging the gap in cancer screening and treatment in Cali, Colombia.
PFCCAP works alongside our sister organization, Fundación Colombiana Para La Prevención y Tratamiento del Cáncer (FCPTC), in Cali, Colombia in the year-round programming highlighted below.
On-the-ground work is led by FCPTC Executive Director, Andrés Pérez, and Patient Navigation Coordinator, Patricia Córdoba.
Left to right: FCPTC Executive Director: Andrés Pérez, PFCCAP Program Director: Tyler Horton, FCPTC Patient Navigation Coordinator: Patricia Córdoba
OUR VISION
A world where lives are saved because all people
have access to the resources needed
for the prevention, early diagnosis, and proper treatment of cancer.
OUR MISSION
To advocate for cancer patients by making connections, providing education, and guiding patient navigation to improve the quality and length of their life; with a focus on breast, cervical, and abdominal cancers.
OUR WORK
For the past 10+ years, we have been focused on mitigating the obstacles women face in their breast and cervical cancer journeys by bridging the gap in cancer screening and treatment in Cali, Colombia. We have also worked to improve the quality of care through continued medical education and teleconferences for the medical community.
OUR FUTURE
PFCCAP is in a huge phase of growth as we launch our Abdominal Cancers Alliance throughout North America. We are a patient-driven organization that will provide accurate information and connections to patients and families so they will get the proper treatment in a timely manner.
Our Team
Dedication. Passion. Expertise.
SMALL TITLE
I'm a paragraph. Click here to add your own text and edit me. It's easy. I'm a paragraph. Click here to add your own text and edit me. It's easy. I'm a paragraph. Click here to add your own text and edit me. It's easy.
DO YOU HAV QUESTIONS? LET US HELP YOU >>
THE ORGANIZATIONS
Event Schedule, September 15, 2025
8:00 - 9:00 am
9:00 am
9:30 am
9:30 am - 3:00 pm
Lunch pickup at the turn
10:30 at driving range
3:00 - 3:30 pm
3:30 - 4:30 pm
-
Arrival and Check-In outside of Clubhouse
-
Light breakfast and coffee will be provided
-
Purchase tickets, mulligans, and entry to play games on course (cash and credit card accepted)
-
Free bucket of balls for driving range
-
Gather for remarks, directions, and rules of the day
-
Shot Gun Start
-
18 hole golf
-
Charity games at various holes
-
11 am lunch starts, pick up hot dogs and hamburgers between holes 9 and 10
-
Drink cart
-
Helicopter Ball Drop (driving range closed until 10:45)
-
Putting competition finals
-
Dinner, programming, awards ceremony, raffle winners drawn
Diagnosis and Prognosis
Although the recommended treatment for all advanced appendix cancers is CRS/HIPEC, prognosis and outcomes are highly dependent on the pathologic subtype. Therefore, accurately diagnosing these tumors is especially important for treatment and surveillance decisions. This can be challenging as the subtypes exist on a spectrum, researchers are still trying to elucidate the best classification system/nomenclature, and many pathologists are unfamiliar with this rare disease. Do not be surprised if your CRS/HIPEC surgeon requests that your pathology slides be reviewed for additional opinions.

Carcinoid/Neuroendocrine
Appendix carcinoid or neuroendocrine tumors (NETs) are commonly found towards the tip of the appendix and are usually detected in the early stages, without extensive abdominal disease. Although less likely than with other intestinal neuroendocrine tumors, appendix carcinoid tumors can secrete serotonin and other substances that cause carcinoid syndrome, characterized by diarrhea, flushing, and cardiac issues.[14] In the early stage, an extended appendectomy or right hemicolectomy may be all that is required. The extent of primary tumor resection and prognosis depends on the size of the tumor. Early-stage carcinoid tumors have an excellent prognosis, with survival of greater than 30 years. In the rare event that they have spread beyond the appendix to the peritoneal cavity (
DPAM/LGMCP
The most common histopathologic subtype is low-grade mucinous carcinoma peritonei (LGMCP), which may also be referred to as DPAM or LAMN. This is a non-invasive subtype that is characterized by large mucin pools and few bland cancerous cells. It originates in a low or high-grade appendiceal mucinous neoplasm (LAMN/HAMN) and progresses to LGMCP/DPAM once it has spread beyond the appendix into the abdominal cavity.[3] It rarely spreads outside of the abdomen or to lymph nodes and is not known to respond to systemic chemotherapy.[16] It is the subtype associated with the longest survival, with median overall survival >15 years after complete CRS/HIPEC. The 10-year overall survival ranges from 75-82%.[8, 17] Although less common than in other subtypes, recurrence can also occur in up to 30% of patients and median progression-free survival is 7-10 years after complete CRS/HIPEC.[18] Emerging evidence demonstrates that the number of cells present in the mucin is directly correlated to recurrence and overall survival, with acellular mucin associated with the best outcomes.[19, 20] Without complete CRS/HIPEC, survival shortens to less than 5 years. Because these tumors illicit a large immune response, some oral chemotherapy agents with an anti-inflammatory component, such as capecitabine (Xeloda), may be offered in unresectable cases.[21]
PMCA/HGMCP
High-grade mucinous carcinoma peritonei (HGMCP), also referred to as PMCA, is an invasive mucinous adenocarcinoma. Outcomes vary based on tumor grade (well, moderately, or poorly differentiated) and the presence of lymph node involvement. Well-differentiated tumors with negative lymph nodes tend to have longer survival outcomes.[3] However, complete CRS with HIPEC is the best treatment for all HGMCP, with median overall survival ranging from 8-10 years.[8, 9, 17] Recurrence is more likely, occurring in up to 45% of patients around 4-5 years after CRS/HIPEC.[17, 18] Without complete CRS/HIPEC, survival shortens to approximately 2-3 years. Systemic chemotherapy with colon-type regimens (FOLFOX, FOLFIRI) may be recommended for patients with unresectable disease or as “preventative” treatment (adjuvant therapy) after complete CRS/HIPEC in patients who are at high risk for recurrence (i.e. positive lymph nodes or poorly differentiated).[11, 22]
PMCA-S/HGMCP-S
Signet ring cell carcinoma or PMCA-S is a type of high-grade mucinous carcinoma peritonei that is highly invasive and aggressive. Signet ring describes the shape of the cancer cells within the mucin, which are characterized by the nucleus pushed to the edge forming a ring and creating a higher propensity for lymph node and distant (extra-abdominal) metastases.[3] The prognosis largely depends on the amount of tumor and the extent of the disease. Patients with lower tumor burden (lower PCI) and no extra-abdominal or lymph node metastases tend to have better survival outcomes. Some centers employ a “PCI cutoff” for signet ring cell tumors and will not perform CRS/HIPEC on patients above that cutoff point. However, some studies have shown that long-term survival can be achieved with CRS/HIPEC, even in patients with a lot of disease (high PCI), if all the visible tumors can be removed. After complete CRS/HIPEC, median overall survival is approximately 3 years, which improves to around 6 years in lymph node-negative patients.[17, 23, 24] Even after complete CRS/HIPEC, recurrence can occur in up to 65% of patients, with a median progression-free survival of approximately 2 years. Most patients with signet ring cells will be recommended to undergo systemic chemotherapy, before and/or after CRS/HIPEC.[18]
PMCA-G/HGMCP-G
Goblet cell carcinomas or PMCA-G is one of the rarest types of high-grade mucinous carcinoma peritonei that can often be mixed with signet ring and neuroendocrine features. Because of its mixed histology and low incidence, it is commonly misdiagnosed as a less aggressive neuroendocrine/carcinoid tumor.[25] However, it behaves more like a carcinoma and survival depends on the stage of disease at diagnosis and the presence of signet ring cells.[26] Once this cancer has spread beyond the appendix, the role of CRS/HIPEC is controversial. However, no other available treatment options can provide the same chance of long-term survival. Some single-center studies have reported a median overall survival of over 4 years, which includes some long-term survivors beyond 5 years, and a median progression-free survival of around 2 years.[18, 27]
Thank you to our 2025 sponsors!
Diamond Sponsor

Gold Sponsors

Milestone Federal Solutions
Silver Sponsors



Bronze Sponsors


Beverage Cart and Lunch Sponsor

Dinner Sponsor
Barbara Valeri
Golf Cart Sponsor

Putting Contest Sponsor

Donors and Supporters


Patient Stories
-
Include patient highlights from talent show with appendix cancer??
-
Jason Hecht (Link to Patient Stories https://mdmercy.com/centers-of-excellence/cancer/treatments-we-offer/surgical-oncology/patient-stories/jason)
-
Stephanie Brennan (pdf article)
Treatment
Surgery:
Almost all appendix cancers will be treated with surgery. The surgery's extent depends on the disease's size, grade, extension, and location. If a tumor is low-grade and confined to the appendix, a simple appendectomy may be the only treatment you need. If involving the cecum, an extended cecectomy will be needed to have clear margins. If the tumor is high-grade but has not perforated the appendix wall, a right hemicolectomy will be needed to make sure that the lymph nodes are not involved and, if so, to make sure that all tumors are completely removed.[6] A right hemicolectomy removes a portion of the colon around the appendix and some nearby blood vessels and lymph nodes. If the tumor has perforated the appendix and spread throughout the abdominal cavity, then a more extensive cytoreductive surgery in which all visible disease and involved structures are removed will be performed.[7] Longer survival is associated with less amount of disease remaining after surgery.[8, 9] It is important to have a surgeon who is experienced with appendix cancers perform your surgery.
Chemotherapy:
In some cases, appendix cancer can be treated with systemic chemotherapy. If there is very extensive disease, preoperative chemotherapy may be recommended to make it more amenable to surgical resection.[7, 10] Depending on surgical results and tumor type, postoperative chemotherapy may be recommended. The most common agents/regimens are those used to treat colon cancer, such as FOLFOX, FOLFIRI, with or without Avastin. Sometimes, XELODA may be used as maintenance therapy.[11, 12]
However, it is important to note that the role of systemic chemotherapy in these tumors is poorly defined and the benefit is not well established. There are no randomized clinical trials studying the effectiveness of systemic chemotherapy in appendix cancer. Data and recommendations are extrapolated from colon cancer studies, even though there is evidence that these tumors are molecularly and behaviorally distinct.[13] An experienced medical oncologist should review your specific case for chemotherapy recommendations.
CRS/HIPEC:
Recent studies have shown a significant increase in survival with the use of extensive cytoreduction (CRS) combined with intraoperative heated intraperitoneal chemotherapy (HIPEC).[7, 8] In fact, CRS/HIPEC is now considered the standard of care treatment for all subtypes of advanced appendix cancers.
In this procedure, a complete cytoreduction is performed, which is the surgical removal of all visible disease. Surgical resections may include parts of an organ or the entire organ and may include: the spleen, gallbladder, liver, peritoneum (lining of the abdominal cavity), uterus, fallopian tubes/ovaries, and bowel. This is followed by heated chemotherapy that is circulated directly into the abdominal cavity to kill any remaining microscopic cancer cells. CRS/HIPEC is the recommended treatment when the appendix has ruptured and there is evidence of disease in the abdominal cavity (peritoneal spread). Patients who undergo complete CRS, with no residual disease (CC-0/1{link to term in Glossary), immediately followed by HIPEC have the best chance at long-term survival.[8, 9]














.png)














.png)






.png)





